- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01962415
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT (HSCT+RIC)
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For some non-malignant diseases (NMD; i.e., thalassemia, sickle cell disease, most immune deficiencies) a hematopoietic stem cell transplant may be curative by healthy donor stem cell engraftment alone. HSCT in patients with NMD differs from that in malignant disorders for two important reasons: 1) these patients are typically naïve to chemotherapy and immunosuppression. This may potentially lead to difficulties with engraftment. And 2) RIC with subsequent bone marrow chimerism may be beneficial even in mixed chimerism and result in decreased transplant-related mortality (TRM). Nevertheless, any previous organ damage, as a result of the underlying disease, may remain present after the HSCT.
For other diseases (metabolic disorders, some immunodeficiencies, etc.), a transplant is not curative. For these diseases, the main intent of the transplant is to slow down, or stop, the progress of the disease. In select few cases/diseases, the presence of healthy bone marrow derived cells may even prevent progression and prevent neurological decline.
In this research study, instead of using the standard myeloablative conditioning, the study doctor is using RIC, in which significantly lower doses of chemotherapy will be used. The lower doses may not eradicate every stem cell in the patient's bone marrow, however, in the presented combination, the intention is to eliminate already formed immune cells and provide maximum growth advantage to healthy donor stem cells. This paves the way to successful engraftment of donor stem cells. Engrafting donor stem cells can outcompete, and donor lymphocytes could suppress, the patients' surviving stem cells. With RIC, the side effects on the brain, heart, lung, liver, and other organ functions are less severe and late toxic effects should also be reduced.
The purpose of this study is to collect data from the patients undergoing reduced-intensity conditioning before HSCT, and compare it to the standard myeloablative conditioning. It is expected there will be therapeutic benefits, paired with better survival rate, less organ toxicity and improved quality of life, following the RIC compared to the myeloablative regimen.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Shawna McIntyre, RN
- Phone Number: 412-692-5552
- Email: mcintyresm@upmc.edu
Study Contact Backup
- Name: Paul Szabolcs, MD
- Phone Number: 412-692-5427
- Email: paul.szabolcs@chp.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- UPMC Children's Hospital of Pittsburgh
-
Contact:
- Shawna McIntyre, RN
- Phone Number: 412-692-5552
- Email: mcintyresm@upmc.edu
-
Sub-Investigator:
- Maria Escolar, MD
-
Sub-Investigator:
- Randy Windreich, MD
-
Sub-Investigator:
- Craig Byersdorfer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion:
- A 4/6, 5/6 or 6/6 HLA matched related or unrelated UCB unit available that will deliver a pre-cryopreservation total nucleated cell dose of ≥ 3 x 10e7 cells/kg, or double unit grafts, each cord blood unit delivering at least 2 x 10e7 cells/kg OR an 8 of 8 or 7 of 8 HLA allele level matched unrelated donor bone marrow or peripheral blood progenitor graft.
Adequate organ function as measured by:
- Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥ 50 mL/min/1.73 m2.
- Hepatic transaminases (ALT/AST) ≤ 4 x upper limit of normal (ULN).
- Adequate cardiac function by echocardiogram or radionuclide scan (shortening fraction > 26% or ejection fraction > 40% or > 80% of normal value for age).
- Pulmonary evaluation testing demonstrating CVC or FEV1/FVC of ≥ 50% of predicted for age and/or resting pulse oximeter ≥ 92% on room air or clearance by the pediatric or adult pulmonologist. For adult patients DLCO (corrected for hemoglobin) should be ≥ 50% of predicted if the DLCO can be obtained.
- Written informed consent and/or assent according to FDA guidelines.
- Negative pregnancy test if pubertal and/or menstruating.
- HIV negative.
A non-malignant disorder amenable to treatment by stem cell transplantation, including but not limited to:
Primary Immunodeficiency syndromes including but not limited to:
- Severe Combined Immune Deficiency (SCID) with NK cell activity
- Omenn Syndrome
- Bare Lymphocyte Syndrome (BLS)
- Combined Immune Deficiency (CID) syndromes
- Combined Variable Immune Deficiency (CVID) syndrome
- Wiskott-Aldrich Syndrome
- Leukocyte adhesion deficiency
- Chronic granulomatous disease (CGD)
- X-linked Hyper IgM (XHIM) syndrome
- IPEX syndrome
- Chediak - Higashi Syndrome
- Autoimmune Lymphoproliferative Syndrome (ALPS)
- Hemophagocytic Lymphohistiocytosis (HLH) syndromes
- Lymphocyte Signaling defects
- Other primary immune defects where hematopoietic stem cell transplantation may be beneficial
Congenital bone marrow failure syndromes including but not limited to:
- Dyskeratosis Congenita (DC)
- Congenital Amegakaryocytic Thrombocytopenia (CAMT)
- Osteopetrosis
Inherited Metabolic Disorders (IMD) including but not limited to:
Mucopolysaccharidoses
- Hurler syndrome (MPS I)
- Hunter syndrome (MPS II)
Leukodystrophies
- Krabbe Disease, also known as globoid cell leukodystrophy
- Metachromatic leukodystrophy (MLD)
- X-linked adrenoleukodystrophy (ALD)
- Hereditary diffuse leukoencephalopathy with spheroids (HDLS)
Other inherited metabolic disorders
- alpha mannosidosis
- Gaucher Disease
- Other inheritable metabolic diseases where hematopoietic stem cell transplantation may be beneficial.
Hereditary anemias
- Thalassemia major
Sickle cell disease (SCD) - patients with sickle disease must have one or more of the following:
- Overt or silent stroke
- Pain crises ≥ 2 episodes per year for past year
- One or more episodes of acute chest syndrome
- Osteonecrosis involving ≥ 1 joints
- Priapism
- Diamond Blackfan Anemia (DBA)
- Other congenital transfusion dependent anemias
Inflammatory Conditions
- Crohn's Disease/Inflammatory Bowel Disease
Exclusion:
- Allogeneic hematopoietic stem cell transplant within the previous 6 months.
- Any active malignancy or MDS.
- Severe acquired aplastic anemia.
- Uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression of clinical symptoms).
- Pregnancy or nursing mother.
- Poorly controlled pulmonary hypertension.
- Any condition that precludes serial follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UCBT:transfusion dependent anemias or increased rejection risk
Day -21 to -19: Alemtuzumab + Hydroxyurea; Day -18 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
|
Oral administration at 30 mg/kg/day.
Other Names:
Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection. Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only.
Other Names:
IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.
Other Names:
IV administration at 70 mg/m2/dose.
Other Names:
IV administration at 200 mg/m2/dose
|
Experimental: BMT, PBSCT and not transfusion dependent UCBT
Start of conditioning to Day -15: Hydroxyurea; Day -14 to -13: Alemtuzumab + Hydroxyurea; Day -12 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
|
Oral administration at 30 mg/kg/day.
Other Names:
Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection. Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only.
Other Names:
IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.
Other Names:
IV administration at 70 mg/m2/dose.
Other Names:
IV administration at 200 mg/m2/dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-transplant treatment-related mortality (TRM)
Time Frame: 1 year post-transplant
|
The number of deaths related to the research intervention at day 100, 6 months, and 1 year post-transplant.
|
1 year post-transplant
|
Neurodevelopmental milestones
Time Frame: 1 year post-transplant
|
Evaluation of the pace of attaining neurodevelopmental milestones after reduced-intensity conditioning as compared to myeloablative conditioning historical controls from the target population(s).
|
1 year post-transplant
|
Immune Reconstitution
Time Frame: 1 year post-transplant
|
Evaluation of the pace of immune reconstitution.
|
1 year post-transplant
|
Severe opportunistic infections
Time Frame: 1 year post-transplant
|
Evaluation of the incidence of severe opportunistic infections.
|
1 year post-transplant
|
GVHD occurrence
Time Frame: 1 year post-transplant
|
Description of the incidence of acute graft versus host disease (GVHD) (II-IV) and chronic extensive GVHD.
|
1 year post-transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Donor cell engraftment
Time Frame: 6 months post-transplant
|
Determination of the feasibility of attaining robust donor cell engraftment (>50% donor chimerism at 6 months) following reduced-intensity conditioning (RIC) regimens prior to HSCT in the target population(s).
|
6 months post-transplant
|
Normal enzyme level
Time Frame: 1 year post-transplant
|
Determination of the feasibility of attaining and sustaining normal enzyme levels in the target population(s).
|
1 year post-transplant
|
Neutrophil recovery
Time Frame: 1 year post-transplant
|
Determination of the pace of neutrophil recovery.
|
1 year post-transplant
|
Platelet recovery
Time Frame: 1 year post-transplant
|
Determination of the pace of platelet recovery.
|
1 year post-transplant
|
Grade 3-4 organ toxicity
Time Frame: 1 year post-transplant
|
The number of grade 3-4 organ adverse events.
|
1 year post-transplant
|
Late graft failure
Time Frame: 1 year post-transplant
|
Evaluation of the incidence of late graft failure.
|
1 year post-transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Szabolcs, MD, University of Pittsburgh
Publications and helpful links
General Publications
- Vander Lugt MT, Chen X, Escolar ML, Carella BA, Barnum JL, Windreich RM, Hill MJ, Poe M, Marsh RA, Stanczak H, Stenger EO, Szabolcs P. Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Adv. 2020 Jul 14;4(13):3041-3052. doi: 10.1182/bloodadvances.2020001940. Erratum In: Blood Adv. 2020 Aug 11;4(15):3508.
- Vander Lugt MT, Chen X, Escolar ML, et al. Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Adv. 2020;4(13):3041-3052. Blood Adv. 2020 Aug 11;4(15):3508. doi: 10.1182/bloodadvances.2020002967. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Inflammatory Bowel Disease
- Crohn's Disease
- Gaucher Disease
- Leukodystrophies
- Hematopoietic Stem Cell Transplant (HSCT)
- Osteopetrosis
- Severe Combined Immune Deficiency (SCID)
- Omenn Syndrome
- Bare Lymphocyte Syndrome (BLS)
- Combined Immune Deficiency (CID) syndromes
- Combined Variable Immune Deficiency (CVID) syndrome
- Wiskott-Aldrich Syndrome
- Leukocyte adhesion deficiency
- Chronic granulomatous disease (CGD)
- X-linked Hyper IgM (XHIM) syndrome
- IPEX syndrome
- Chediak - Higashi Syndrome
- Autoimmune Lymphoproliferative Syndrome (ALPS)
- Hemophagocytic Lymphohistiocytosis (HLH) syndromes
- Lymphocyte Signaling defects
- Dyskeratosis Congenita (DC)
- Congenital Amegakaryocytic Thrombocytopenia (CAMT)
- Mucopolysaccharidoses
- Hurler syndrome (MPS I)
- Hunter syndrome (MPS II)
- Krabbe Disease
- Metachromatic leukodystrophy (MLD)
- X-linked adrenoleukodystrophy (ALD)
- Alpha mannosidosis
- Thalassemia major
- Sickle cell disease (SCD)
- Diamond Blackfan Anemia (DBA)
- Congenital transfusion dependent anemias
- Globoid cell leukodystrophy
- Hereditary diffuse leukoencephalopathy with spheroids (HDLS)
- Systemic Juvenile Idiopathic Arthritis (sJIA)
Additional Relevant MeSH Terms
- Pathologic Processes
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Autoimmune Diseases
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Cytopenia
- Syndrome
- Arthritis
- Primary Immunodeficiency Diseases
- Anemia
- Arthritis, Juvenile
- Metabolic Diseases
- Bone Marrow Failure Disorders
- Pancytopenia
- Congenital Bone Marrow Failure Syndromes
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Antisickling Agents
- Melphalan
- Fludarabine
- Hydroxyurea
- Thiotepa
- Alemtuzumab
Other Study ID Numbers
- PRO13100018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Bone Marrow Failure Syndromes
-
Sohag UniversityAssiut University; Kyoto UniversityRecruitingInherited BMF SyndromeEgypt
-
National Cancer Institute (NCI)RecruitingInherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid MalignanciesUnited States
-
Franziska WachterHarvard Clinical and Translational Science Center (Harvard Catalyst)RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | MDS | Aml | Myeloid Neoplasm | Myeloid Malignancies | Inherited Bone Marrow Failure SyndromeUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingSevere Aplastic Anemia | Telomere Biology Disorders | Inherited Bone Marrow Failure SyndromesUnited States
-
University of California, San FranciscoTerminatedMyeloid Malignancy | Metabolic Disease | Bone Marrow Failure Syndrome | Transfusion-dependent Red Blood Cell (RBC) Defect | Congenital Immunodeficiency | Severe Immune DysregulationUnited States
-
Cellenkos, Inc.Active, not recruitingBone Marrow DiseaseUnited States
-
Peter MacCallum Cancer Centre, AustraliaNational Health and Medical Research Council, Australia; University of MelbourneRecruitingHematologic Diseases | Inherited Platelet Disorder | Inherited BMF SyndromeAustralia
-
Medical College of WisconsinChildren's Hospital of PhiladelphiaCompletedMalignant Diseases (ie, Leukemia, MDS, Lymphoma) | Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)United States
-
Talaris Therapeutics Inc.Duke UniversityWithdrawnAnemia, Sickle Cell | Thalassemia | Beta-Thalassemia | Bone Marrow Failure Syndromes | Diamond-Blackfan Anemia | Alpha-Thalassemia | Complex and Transfusion-dependent HemoglobinopathiesUnited States
-
Children's Hospital of PhiladelphiaAvailableLeukemia | Immunodeficiencies | Bone Marrow Failure SyndromeUnited States
Clinical Trials on Hydroxyurea
-
Shiraz University of Medical SciencesCompletedCombination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermediaβ-Thalassemia IntermediaIran, Islamic Republic of
-
Vanderbilt University Medical CenterAminu Kano Teaching Hospital; Murtala Muhammed Specialist HospitalCompletedStroke | Sickle Cell Disease | Sickle Cell AnemiaNigeria
-
Ain Shams UniversityUnknownThalassemia IntermediaEgypt
-
Vanderbilt University Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Aminu Kano... and other collaboratorsCompletedStroke | Sickle Cell DiseaseNigeria
-
ItalfarmacoCompletedPolycythemia VeraItaly
-
St. Jude Children's Research HospitalTerminatedSickle Cell Disease | ThalassemiaUnited States
-
UNICANCERCompletedBrain and Central Nervous System TumorsFrance
-
St. Jude Children's Research HospitalCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Anemia, Sickle Cell | Hemoglobinopathies
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompletedAdult MeningiomaUnited States